For the first time, Weng and coworkers [78] described the signaling axis SPI1-METTL14-MYB/MYC in normal myelopoiesis and leukemogenesis and proposed that METTL14 could be a new therapeutic target to treat acute myeloid leukemia (AML). This evidence concerns the gene MYB and acute myeloid leukemia.